- There are many medical benefits to cannabis and CBD (cannabidiol) and they are increasingly recognized by the scientific community
- In the past six years, 10 states have legalized cannabis for adult use and the 2018 Farm Bill legalizes industrial hemp as a crop
- As patients and the medical community embrace cannabis and CBD for pain relief, harm and even deaths from opioids will diminish
- Los Sueños Farms outside of Pueblo, Colorado, the largest U.S. cannabis farm with 36 acres and 36,000 plants, shows how technologically advanced the industry has become
- The existence of cannabinoid receptors in humans and other mammals, called the endocannabinoid system, gives clues to why cannabis and CBD affect so many body systems positively
- Many industries, from Big Pharma to the alcohol, lumber, gas and oil and clothing industries, could lose profits from a booming cannabis industry
Production of cannabis is booming as the medical benefits of CBD (cannabidiol) are increasingly recognized.
According to Project CBD, at least 50 conditions1 are believed to be improved by CBD, including pain, seizures, muscle spasms, nausea associated with chemotherapy, digestive disorders such as colitis and inflammatory bowel disease (IBD), degenerative neurological disorders such as dystonia, multiple sclerosis, Parkinson’s disease, mood disorders, anxiety, PTSD and high blood pressure.
Yet, despite the legalization of cannabis for adult use in 10 states in the past few years and the inclusion in the 2018 Farm Bill of industrial hemp as a crop,2 the U.S. Food and Drug Administration (FDA), up until recently, listed CBD as a Schedule I drug, the most dangerous drug category reserved for drugs like heroin and LSD.
The classification made no sense because CBD is nonpsychoactive — it is not addictive, does not produce a “high” and there are few to no dangerous side effects. In fact, there seems no reason for the FDA and Drug Enforcement Agency’s (DEA) long-term vilification of CBD except possible collusion with Big Pharma, whose dangerous and lucrative pain treatments, primarily opioids, would suffer from wider CBD use.
Opioids cause approximately 115 Americans’ deaths every day. In states where CBD is becoming widely used, there are few reports of negative social or medical consequences. Conversely, there are early reports in those same states of fewer opioid emergencies, overdoses and deaths.
The restrictive, Schedule I classification of CBD has also produced medical “refugees” — people whose health conditions are only improved by CBD, not pharmaceutical products, forcing them to relocate to states with looser CBD laws.
A Surprising but Suspicious Change in CBD Classification
At the end of 2018, FDA surprised many with this modification of the Schedule I classification for some CBD products:3
“With the issuance of this final order, the Acting Administrator of the Drug Enforcement Administration places certain drug products that have been approved by the Food and Drug Administration (FDA) and which contain cannabidiol (CBD) in schedule V of the Controlled Substances Act (CSA). Specifically, this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.
This action is required to satisfy the responsibility of the Acting Administrator under the CSA to place a drug in the schedule he deems most appropriate to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961.”
Schedule V drugs are considered to have a lower potential for abuse than other controlled drugs.4The category includes drugs whose benefits may outweigh risks such as those for antidiarrheal, antitussive and analgesic conditions such as cough preparations with less than 200 milligrams of codeine like Robitussin AC, Lomotil, Motofen, Lyrica and Parepectolin.
Yet, does the recent modification of schedule status really reflect new realism on the part of the FDA, or is it simply a nod to drug makers’ desire to “get in on the action” and market share? After all, we have seen a similar phenomenon when Big Pharma attacks the reliability, effectiveness and quality control of popular supplements and vitamins while hypocritically seeking to market the same products themselves.
Cannabis Farms Are Becoming Large and Efficient
The Los Sueños Farms,5 outside of Pueblo, Colorado, with 36,000 plants, depicted in a recent video called “Largest Outdoor Cannabis Farm in World, Canna Cribs Episode 4,” from Growers Network, reveals how technologically far the industry has come.
The 36-acre farm, which consists of four separate farms, processes 40,000 pounds of “biomass” each harvest. Depending on the genetic expression of the plants, some are grown outside, some in greenhouses and some in greenhouses with no walls to allow solar maximization while permitting fresh air to circulate and prevent too much heat from accumulating.
For the outdoor plants, an advanced drip watering system with an emitter every 12 inches provides pressure compensated irrigation and the ability to provide specific nutrients. Drones with several lenses hover above the plants and report back their respiration rate, any insects or disease risks and plants that might be struggling for one reason or another. Humidity and lighting are computer controlled for indoor plants.
When the crop is ready, cannabis flowers are dry trimmed in an advanced piece of machinery called a twister. While the machinery does not require human labor, a quality control person does inspect the product as it comes out of the twister to make sure all stems have been removed at their base.
Cannabis Post Production Processing Is Crucial for Quality
Fertility and nutrients are important, say Los Sueños Farm employees, but the quality of the product itself comes down to curing. In massive curing rooms, racks of product dry at a temperature of 64 degrees Fahrenheit and are made ready for packaging in seven to 10 days.
They are then vacuum packed and nitrogen sealed in 10-pound bags. The bags have a window so customers can view the cannabis and assess its quality without exposing it to the harmful effects of light or environmental humidity.
After the cannabis leaves Los Sueños Farms, preparation continues for the end user. At processing facilities and retail dispensaries like the Colorado-based Mesa Organics, a partner of Los Sueños, sophisticated extraction methods are then used to cull the raw crude extract from the plant material.
At Mesa Organics, supercritical CO2 is used for the extraction process, not hydrocarbons, says owner Jim Parco, because “any hydrocarbons that are burned over 900 degrees convert to benzene” which can be lethal.
In fact, hydrocarbon extraction is banned in some parts of California, says Parco, because of the “occupational risks to the communities.” The use of supercritical CO2 also creates a purer product. After lipids, waxes and terpenes are removed through extraction, CBD, THC and other cannabinoids from the plant remain and the product is ready to be marketed. TAP – why extract terpenes? They are part of the benefit. Get your cannabis direct and liquidise or chew it.